Marshall Wace LLP Grows Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Marshall Wace LLP boosted its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 83.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 297,499 shares of the biopharmaceutical company’s stock after buying an additional 135,426 shares during the quarter. Marshall Wace LLP owned approximately 0.61% of Theravance Biopharma worth $2,523,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Kennedy Capital Management LLC grew its position in shares of Theravance Biopharma by 3.7% during the 1st quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 1,359 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Theravance Biopharma by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 3,532 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Theravance Biopharma by 66.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 3,824 shares during the period. State Board of Administration of Florida Retirement System increased its position in Theravance Biopharma by 28.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 4,990 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Theravance Biopharma by 11.7% in the second quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 6,026 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on TBPH. Leerink Partnrs lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Monday, September 16th. TD Cowen dropped their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a report on Tuesday, August 6th. Finally, StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $13.75.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Theravance Biopharma news, major shareholder Eli Samaha acquired 999,800 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was acquired at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the purchase, the insider now directly owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 335,965 shares in the company, valued at $3,023,685. The disclosure for this sale can be found here. 6.90% of the stock is owned by corporate insiders.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $8.10 on Friday. The firm has a market cap of $396.25 million, a price-to-earnings ratio of -9.42 and a beta of 0.24. The firm has a fifty day moving average price of $8.36 and a 200 day moving average price of $8.82. Theravance Biopharma, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. The company had revenue of $14.26 million for the quarter, compared to the consensus estimate of $15.81 million. During the same period last year, the company earned ($0.28) EPS. As a group, research analysts predict that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.